NDA 020830 · Organon
Singulair
Montelukast Sodium · Oral
Last checked: Nov 20, 2026Latest source record: Feb 22, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Feb 20, 1998
Approved uses
8
Original approval plus efficacy supplements
Registered trials
344
88 Phase 3, 15 recruiting
FAERS reports
123,347
74,156 serious, 5,007 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS NEUROPSYCHIATRIC EVENTS Serious neuropsychiatric (NP) events have been reported with the use of SINGULAIR. The types of events reported were highly variable, and included, but were not limited to, agitation, aggression, depression, sleep disturbances, suicidal thoughts and behavior (including suicide). The mechanisms underlying NP events associated with SINGULAIR use are currently not well understood [see Warnings and Precautions (5.1) ] . Because of the risk of NP events, the benefits of SINGULAIR may not outweigh the risks in some patients, particularly when the symptoms of disease may be mild and adequately treated with alternative therapies. Reserve use of SINGULAIR for patients with allergic rhinitis who have an inadequate response or intolerance to alternative therapies [see Indications and Usage (1.3) ] . In patients with asthma or exercise-induced...
What it is approved for
From the label in effect Apr 30, 2025.
SINGULAIR is a leukotriene receptor antagonist indicated for: Prophylaxis and chronic treatment of asthma in patients 12 months of age and older ( 1.1 ). Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older ( 1.2 ). Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2 years of age and older, and perennial allergic rhinitis (PAR) in patients 6 months of age and older. Reserve use for patients who have an inadequate response or intolerance to alternative therapies ( 1.3 ). Limitations of Use: Not indicated to treat an acute asthma attack ( 5.2 ). 1.1 Asthma SINGULAIR ® is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. 1.2 Exercise-Induced Bronchoconstriction (EIB) SINGULAIR is indicated for prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older. 1.3 Allergic Rhinitis SINGULAIR is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older. Because the benefits of SINGULAIR may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see Warnings and Precautions (5.1) ] , reserve use for patients who have an inadequate response or intolerance to alternative therapies. 1.4 Limitations of Use SINGULAIR is not indicated for the treatment of an acute asthma attack.
Mechanism: The cysteinyl leukotrienes (LTC 4 , LTD 4 , LTE 4 ) are products of arachidonic acid metabolism and are released from various cells, including mast cells and eosinophils. These eicosanoids bind to cysteinyl leukotriene (CysLT) receptors. The CysLT type-1 (CysLT 1 ) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis. In asthma, leukotriene-mediated effects include airway...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 26, 2012 Supplement 61 · Efficacy LabelLetter
- Apr 13, 2007 Supplement 38 · Efficacy LabelLetter
- Nov 30, 2005 Supplement 36 · Efficacy LabelLetter
- Jul 27, 2005 Supplement 35 · Efficacy LabelLetter
- Dec 31, 2002 Supplement 20 · Efficacy LetterLabel
- Nov 23, 2001 Supplement 11 · Efficacy LetterLabel
- Mar 3, 2000 Supplement 8 · Efficacy LabelReviewLetter
- Feb 20, 1998 Original approval · Type 3 - New Dosage Form LetterReviewOther Important Information from FDA
2 products under this application
- SINGULAIR · MONTELUKAST SODIUM EQ 5MG BASE · TABLET, CHEWABLE, ORAL · Prescription · TE AB
- SINGULAIR · MONTELUKAST SODIUM EQ 4MG BASE · TABLET, CHEWABLE, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Montelukast" as an intervention, any sponsor and status, largest first.
- ACTIV-6: COVID-19 Study of Repurposed MedicationsPivotal-lookingCompleted
Susanna Naggie, MDAcademic, hospital or other
NCT04885530 · 10,956 participants · Start Jun 8, 2021 · Primary completion Apr 29, 2024
Drug: Ivermectin; Fluvoxamine and 3 more · For: Covid19
Sites: Chandler, Arizona; Gilbert, Arizona; Mesa, Arizona · 110 sites in all
- The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00092118 · 1,992 participants · Start Oct 2003 · Primary completion May 2004
Drug: Montelukast; Comparator: Placebo · For: Rhinitis, Allergic, Perennial
- Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00337675 · 1,771 participants · Start Oct 2006 · Primary completion Aug 2009
Drug: montelukast sodium; Comparator: Placebo (unspecified) and 1 more · For: Asthma
- Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00284856 · 1,640 participants · Start May 2006 · Primary completion Apr 2010
Drug: montelukast sodium; Comparator: Placebo and 2 more · For: Asthma
- DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in AdultsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00252863 · 1,600 participants · Start Dec 2004
Drug: Symbicort, used twice daily (b.i.d) and as needed (prn); Budesonide Turbuhaler 200 µg and 11 more · For: Asthma
Sites: Stuttgart, Germany; München, Germany; Cottbus, Germany · 169 sites in all
- Montelukast in Patients With Seasonal Allergic Rhinitis - Spring 2000 Study (MK-0476A-162)(COMPLETED)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00979901 · 1,577 participants · Start Mar 2000 · Primary completion May 2000
Drug: Comparator: montelukast; Comparator: loratadine and 2 more · For: Seasonal Allergic Rhinitis
- ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)Pivotal-lookingCompleted
Susanna Naggie, MDAcademic, hospital or other
NCT05894577 · 1,453 participants · Start Jan 27, 2023 · Primary completion Jul 31, 2023
Drug: Montelukast · For: Covid19
Sites: Chandler, Arizona; Gilbert, Arizona; Mesa, Arizona · 109 sites in all
- An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00127647 · 1,375 participants · Start Nov 2004 · Primary completion Apr 2005
Drug: montelukast sodium; Comparator: pranlukast · For: Rhinitis, Allergic, Seasonal
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- asthma15,205
- dyspnoea15,084
- drug ineffective9,422
- cough9,228
- fatigue8,837
- headache8,389
- wheezing7,763
- pneumonia7,167
- nausea6,920
- pain6,688
- malaise5,385
- dizziness4,955
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,613 |
| 2005 | 1,707 |
| 2006 | 1,908 |
| 2007 | 2,149 |
| 2008 | 3,591 |
| 2009 | 3,025 |
| 2010 | 3,506 |
| 2011 | 3,559 |
| 2012 | 4,455 |
| 2013 | 5,045 |
| 2014 | 4,415 |
| 2015 | 5,984 |
| 2016 | 8,194 |
| 2017 | 6,321 |
| 2018 | 7,118 |
| 2019 | 8,121 |
| 2020 | 8,598 |
| 2021 | 7,917 |
| 2022 | 7,807 |
| 2023 | 6,744 |
| 2024 | 7,752 |
| 2025 | 7,713 |
| 2026 | 6,101 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Singulair (Montelukast Sodium)
2024 spending
$5.7M
Beneficiaries
2,574
11,085 claims
Per beneficiary
$2,222
$8.34 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $1,862,299 |
| 2022 | $6,793,461 |
| 2023 | $6,621,306 |
| 2024 | $5,720,021 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Montelukast.
Markham A, Faulds D · Drugs 1998 · Clinical Trial, Randomized Controlled Trial
- Montelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis.
Mayoral K, Lizano-Barrantes C, Zamora V, et al. · Eur Respir Rev 2023 · Meta-Analysis, Systematic Review
- Neuropsychiatric events associated with montelukast in patients with asthma: a systematic review.
Lo CWH, Pathadka S, Qin SX, et al. · Eur Respir Rev 2023 · Systematic Review
- Efficacy and safety of montelukast-levocetirizine combination therapy in combined allergic rhinitis and asthma syndrome: a systematic review and meta-analysis.
Shao M, Sun J, Zheng Q · J Asthma 2025 · Meta-Analysis, Systematic Review
- Comparative Efficacy of Mometasone Nasal Spray Combined with Different Doses of Desloratadine, and Montelukast in Childhood Allergic Rhinitis: A Randomized Clinical Trial.
Ghanbari N, Eftekhari K, Samadzadeh-Mamaghani M, et al. · Iran J Allergy Asthma Immunol 2024 · Randomized Controlled Trial, Comparative Study
- Leukotriene receptor antagonists for eczema.
Ferguson L, Futamura M, Vakirlis E, et al. · Cochrane Database Syst Rev 2018 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Organon
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.